• Radiation Oncology

    __00.png Call 607-547-3336


    Radiation therapy provides an important modality for the cancer patient. It is one of the primary modalities for treatment of many cancers, and it is also used to provide control of the tumor and relieve pain for nearly all types of cancers, either when they are first diagnosed or if they recur.

    The Bassett Cancer Institute utilizes state-of-the-art radiation oncology technology, the newest procedures, and a highly trained team of physicians and allied professionals to treat cancer patients. Using the latest radiation oncology equipment, staff design the safest, most effective treatments to minimize side effects. The Cancer Institute offers an extensive radioactive implant program, including prostate seed implant therapy.

    • Technology
    • Trilogy Linear Accelerator 
    • 3D Computerized Treatment Planning 
    • High Dose Rate Afterloading Brachytherapy 
    • Intensity Modulated Radiation Therapy (IMRT) 
    • Image Guided Radiation Therapy (IGRT) 
    • Mammosite 

    Bassett Medical Center is the first treatment center in central New York and one of the few institutions nationwide to offer SpaceOAR hydrogel, a pioneering new tool that protects prostate cancer patients from  radiation therapy.

    The hydrogel:

    • is administered as a liquid that quickly solidifies into soft gel,  
    • expands the space between the prostate and rectum, and
    • shields rectal tissue from radiation exposure, reducing side effects during treatment.

     Bassett Cancer Institute has begun treating patients with a new radiation oncology radiopharmaceutical therapy, Radium-223 (Xofigo), that targets bone metastases from prostate cancer. This therapy is an intravenous infusion used for castration resistant prostate cancer bone palliation. Bassett is one of the few facilities across the nation to offer this innovative treatment to patients. Benefits of Xofigo:

    • Cutting-edge therapy
    • Reduces the number of times patients need to travel for treatment (one treatment per month for six months)
    • Bassett Cancer Institute is the only facility in the region that offers this treatment

    Additionally, Bassett Cancer Institute is now offering Selective Internal Radiation Therapy (SIRT) with Yttrium-90 microspheres that target liver tumors.

    Colorectal cancer often metastasizes to the liver. When this occurs, treatment options are limited. Approximately 10 percent of patients may be candidates for surgery (resection with good survival benefits). Of the remaining patients, 70 percent to 80 percent will die as a result of liver failure. SIRT is a treatment approach that allows for millions of tiny spheres coated in beta radiation to be delivered to liver tumors directly, sparing the other vital healthy liver tissue from radiation damage. This treatment provides a significant benefit, has limited toxicities and is an outpatient procedure. Until recently, this very beneficial therapy was only offered at large academic cancer institutions; now, it is offered at Bassett Cancer Institute, allowing patients to remain close to home while the procedure is performed locally by a team of physicians in Medical Oncology, Radiation Oncology and Interventional Radiology.

    The department continues to offer the newest radiation oncology treatment techniques. Staff members have presented their extensive experience with these approaches at national cancer meetings since 1997.